|
Deeken, John F; Beumer, Jan H; Anders, Nicole M et al. (2015) Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemother Pharmacol 76:813-9
|
|
Beumer, J H; Venkataramanan, R; Rudek, M A (2014) Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther 95:370-2
|
|
Rudek, Michelle A; Chang, Cathy Y; Steadman, Kenneth et al. (2014) Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol 73:729-36
|
|
Wang, S E; Yu, Y; Criswell, T L et al. (2010) Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene 29:3335-48
|
|
Bauer, Joshua A; Ye, Fei; Marshall, Clayton B et al. (2010) RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 12:R41
|
|
Rexer, Brent N; Engelman, Jeffrey A; Arteaga, Carlos L (2009) Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8:18-22
|
|
Wang, Shizhen Emily; Hinow, Peter; Bryce, Nicole et al. (2009) A mathematical model quantifies proliferation and motility effects of TGF-? on cancer cells. Comput Math Methods Med 10:71-83
|
|
Wang, Shizhen Emily; Xiang, Bin; Zent, Roy et al. (2009) Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69:475-82
|
|
Guix, Marta; Mayer, Ingrid A; Meszoely, Ingrid M et al. (2008) Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res 10 Suppl 4:S25
|
|
Yang, Seungchan; Park, Kyungho; Turkson, James et al. (2008) Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res 314:413-9
|
Showing the most recent 10 out of 62 publications
